Home / Market News / $PCVX
benzinga Corporate Catalyst Impact 85/100 ● positive

Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxive

Oct 5, 2026, 10:06 AM UTC · Primary ticker $PCVX

Vaxcyte announced positive topline results from its OPUS-1 Phase 3 trial for VAX-31, a pneumococcal vaccine candidate, meeting all primary endpoints. This successful trial significantly de-risks the development of VAX-31 and positions Vaxcyte as a strong contender in the pneumococcal vaccine market, potentially impacting competitors.

Vaxcyte reported that its VAX-31 pneumococcal conjugate vaccine candidate met all prespecified primary endpoints in the OPUS-1 pivotal adult Phase 3 trial. This includes noninferiority to Prevnar 20 (PCV20) and Capvaxive (PCV21) for shared serotypes, and superiority for unique VAX-31 serotypes. This is a critical milestone for Vaxcyte, validating its carrier-sparing platform and paving the way for a Biologics License Application submission in the first half of 2028. For traders, this represents a significant long-term opportunity for Vaxcyte (PCVX) as it enters a lucrative market, while posing a competitive threat to established players like Pfizer (PFE) and Moderna (MRNA) in the short to medium term as VAX-31 progresses towards commercialization.

$PCVX positive Successful Phase 3 trial results
$PFE negative Increased competition for Prevnar 20
$MRNA negative Increased competition for Capvaxive
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.